PIK3CA testing in HR+/HER2− Metastatic Breast Cancer: Real-world data from referral molecular pathology labs

PIK3CA testing in HR+/HER2− Metastatic Breast Cancer: Real-world data from referral molecular pathology labs

Saved in:

Bibliographic Details
Main Authors:	K. Venetis, G. Cursano, F. Pepe, C. Frascarelli, P. Pisapia, D. Vacirca, C. Scimone, A. Rappa, E. Mane, G. Troncone, E.G. Rocco, U. Malapelle, N. Fusco
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	The Journal of Liquid Biopsy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950195423001248
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer
by: Elizabeth J. Anderson, et al.
Published: (2020-01-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

A Narrow NGS Panel in the Analysis of KRAS p.G12C Mutation in Longitudinal Series of NSCLC Patients: A Pilot Study
by: F. Pepe, et al.
Published: (2023-11-01)

Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real-World Study in Croatia
by: Dora Čerina Pavlinović, et al.
Published: (2024-01-01)

Liquid biopsy: Cell-free DNA based analysis in breast cancer
by: Konstantinos Venetis, et al.
Published: (2023-09-01)

Technical evaluation of a novel digital PCR platform for detecting EGFR/KRAS mutations in NSCLC archived plasma specimens
by: Claudia Scimone, et al.
Published: (2024-03-01)

Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer
by: Chiara Frascarelli, et al.
Published: (2024-12-01)

Lichenoid dermatitis induced by abemaciclib in a patient with HR+/HER2- breast cancer
by: Edoardo Mortato, et al.
Published: (2024-11-01)

Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer
by: Jing-Jing Liu, et al.
Published: (2024-11-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
by: Yoonwon Kook, et al.
Published: (2024-11-01)

Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
by: Yoonwon Kook, et al.
Published: (2024-11-01)

The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis
by: Shiwei Liu, et al.
Published: (2025-01-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

P53 and PIK3CA Mutations in KRAS/HER2 Negative Ovarian Intestinal-Type Mucinous Carcinoma Associated with Mature Teratoma
by: Sarah Bouri, et al.
Published: (2020-01-01)

HR Service Formation and Development as Organization Competitiveness Factor
by: G. G. Biganova, et al.
Published: (2017-09-01)

Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01)

Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer
by: Ram Patel, et al.
Published: (2025-01-01)

IMPROVING QUALITY THROUGH INNOVATIONS: THE ROLE OF VENTURE FINANCING AND HR SUPPORT
by: Doston T. Turgunov, et al.
Published: (2025-03-01)

The “lows”: Update on ER-low and HER2-low breast cancer
by: Nicola Fusco, et al.
Published: (2024-12-01)

Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01)

Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor‐positive, HER2‐negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
by: Anja Welt, et al.
Published: (2020-07-01)

TRENDS IN HR MANAGEMENT AT THE ENTERPRISE
by: Svitlana Babych, et al.
Published: (2023-12-01)

KOMPOSISI MUSIK "PIK-PIK-NUMPANG-TIDUK": INTERPRETASI DARI SEBUAH KESENIAN TRADISI LISAN DI DESA PULAU TEMIANG, KABUPATEN TEBO, PROVINSI JAMBI
by: Hadaci Sidik
Published: (2018-09-01)

Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant
by: Patsy R Tomlinson, et al.
Published: (2025-01-01)

Coworking, fab labs et living labs
by: Arnaud Scaillerez, et al.
Published: (2017-06-01)

How Odynerus Suspends Her Egg
by: Carl G. Hartman
Published: (1944-01-01)

Oncogenic PIK3CA corrupts growth factor signaling specificity
by: Ralitsa R Madsen, et al.
Published: (2024-12-01)

FINANCIAL AND HR MANAGEMENT OF TOURISM ENTERPRISES
by: Марта Барна, et al.
Published: (2024-12-01)

HR Tech and staff training interaction
by: N. Yu. Kaufman, et al.
Published: (2022-07-01)

Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28)
by: Yifan Chen, et al.
Published: (2024-12-01)

Association of PIK3CA somatic mutations with clinicopathological parameters in breast cancer
by: Gizem Teoman, et al.
Published: (2024-12-01)

Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node-Positive HR+, HER2− Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta-Analysis
by: Mahtab Vasigh, et al.
Published: (2024-01-01)

УПРАВЛІННЯ ДІДЖИТАЛІЗАЦІЄЮ HR-ПРОЦЕСІВ В БІЗНЕСІ
by: Вероніка Командровська, et al.
Published: (2024-11-01)

Post-Pandemic HR Trends in Romania and beyond
by: H. Moasa
Published: (2020-07-01)

Evaluation of Cell-Free DNA Long Fragments in the Triage of FIT+ Patients Enrolled in a Colorectal Cancer Screening Program: An Italian Prospective, Cross-Sectional Study
by: Mauro Scimia, et al.
Published: (2024-12-01)

Oncogenic activation of PIK3CA in cancers: Emerging targeted therapies in precision oncology
by: Yuxiang Wang, et al.
Published: (2025-03-01)

Characterizing Superflares in HR 1099 Using Temporal and Spectral Analysis of XMM-Newton Observations
by: Shweta Didel, et al.
Published: (2024-01-01)

Biochemistry in the Lab : a manual for undergraduates /
by: Lasseter, Benjamin F.
Published: (2020)

Biochemistry in the Lab : a manual for undergraduates /
by: Lasseter, Benjamin F.
Published: (2020)